ATRC

AtriCure, Inc. 10-Q Summary: Quarter Ended June 30, 2010

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for AtriCure, Inc., a medical device company specializing in cardiac surgical ablation systems and left atrial appendage exclusion devices. The reporting period covers the three and six months ended June 30, 2010. The company operates as a single segment, selling primarily to hospitals and medical centers in the United States and internationally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 3.0% for the quarter and 2.5% for the six-month period compared to the prior year. Growth was driven by U.S. sales of the Cryo1 device, partially offset by a decline in international revenue due to the transition from a distributor to a direct sales model in Europe.
• Profitability: The net loss narrowed significantly compared to the prior year. The six-month net loss decreased from $9.41 million in 2009 to $2.77 million in 2010. This improvement is largely due to the absence of a $6.81 million goodwill impairment charge recorded in the first quarter of 2009.
• Operating Expenses: Research and development (R&D) expenses decreased by $0.7 million (quarter) and $1.0 million (six months) due to the completion of enrollment in certain clinical trials. Selling, general, and administrative (SG&A) expenses increased by $0.7 million (quarter) and $1.5 million (six months) primarily due to increased headcount in sales and marketing.
• Liquidity: Cash and cash equivalents decreased by $2.05 million during the six-month period, primarily due to operating losses, inventory build-up, and debt repayments.

Guidance, Outlook, and Risks

• Product Launches: The company received FDA clearance for the AtriClip system in June 2010 and initiated a limited commercial release. The Linear Multifunctional Pen also received FDA clearance, with a planned U.S. release in Q4 2010.
• Regulatory Matters: The company submitted a 510(k) filing for its Isolator Synergy clamps to address FDA concerns regarding the indication for cardiac tissue ablation. The FDA requested additional information in July 2010.
• Legal Settlements: The company finalized a settlement with the Department of Justice (DOJ) regarding False Claims Act allegations. A liability of approximately $3.52 million remains, with payments scheduled over five years. The company expects to recover these costs via insurance.
• Outlook: Management anticipates R&D expenses to increase in the second half of 2010 to support the DEEP AF clinical trial and the final ABLATE PMA submission. The company believes current cash and credit facilities are sufficient to meet needs for the next 12 months.
• Risks: Key risks include the impact of healthcare reform legislation (including a 2.3% excise tax on medical devices), the outcome of ongoing regulatory reviews, and the ability to secure additional financing if cash flows are insufficient.

Investor Verification Checklist

• Regulatory Status: Verify the status of the 510(k) submission for the Isolator Synergy clamps and the FDA's response to the July 2010 information request.
• DOJ Settlement: Confirm the insurance recovery status for the DOJ settlement costs and the schedule of future payments.
• European Transition: Monitor the financial impact of the transition from a distributor to a direct sales model in Europe, including the costs of the distributor termination and the new consulting agreement.
• Credit Facility: Review the terms of the August 2010 credit facility modification, which increased borrowing capacity to approximately $7.5 million.
• Inventory Levels: Assess the rationale for the $1.2 million increase in inventory and the risk of obsolescence given the rapid product development cycle.